Medical insurance does cover varicose vein treatment, but only when the condition is documented as medically necessary. That means veins causing symptoms like pain, swelling, skin changes, bleeding, or ulceration, confirmed by a duplex ultrasound, and usually treated first with compression stockings before a procedure is approved. Treatment aimed only at appearance, including most spider vein work, is excluded by nearly every insurer and by Medicare.
Medically Necessary vs. Cosmetic
Insurers draw a hard line between veins that cause a health problem and veins that are a cosmetic concern. Symptoms and findings that generally qualify for covered treatment include venous ulcers (open or healed), bleeding from a ruptured varicosity, recurrent superficial thrombophlebitis, persistent pain or swelling that interferes with daily activities, work, or sleep, and skin changes like discoloration or stasis dermatitis near the ankles.
Spider veins and small reticular veins that cause no symptoms are classified as cosmetic by virtually every insurer, including Medicare. The usual exception is when they bleed or sit over documented underlying venous insufficiency producing physical symptoms.
Many insurer policies also reference the CEAP classification. Several Blue Cross plans require a clinical stage of C2 or greater, which means varicose veins typically 3 millimeters or larger, before coverage will even be considered. Reaching that stage is necessary but not sufficient on its own.
The Duplex Ultrasound Thresholds
Before any insurer approves a procedure, you’ll need a duplex ultrasound confirming the diagnosis. The study measures blood flow direction, vein diameter, and valve function, and it is the standard test for venous reflux.
Insurers want specific numbers from that report. Most policies require venous reflux lasting at least 500 milliseconds, measured with the patient standing or in a reverse Trendelenburg position. Vein diameter thresholds vary by carrier:
- UnitedHealthcare requires the great saphenous vein to be at least 3 millimeters.
- Aetna requires 4.5 millimeters for saphenous veins and 3.5 millimeters for perforating veins.
- TRICARE requires at least 3.5 millimeters.
The ultrasound typically has to have been performed within the last 6 to 12 months, depending on the insurer. Without an ultrasound that meets these numeric thresholds, the claim will almost certainly be denied no matter how symptomatic you are.
The Conservative Treatment Trial
Most insurers require a documented trial of conservative management before authorizing a procedure. That generally means medical-grade graduated compression stockings (usually 20 to 30 mmHg), along with leg elevation, exercise, weight management, and sometimes anti-inflammatory medication. Required durations vary:
- UnitedHealthcare: as short as two weeks.
- Anthem: six weeks.
- Medicare, Aetna, Cigna, and TRICARE: three months.
- Blue Cross Blue Shield: three months, though this varies by plan.
Keep receipts for your compression stockings and note when you started wearing them. Gaps in documentation are a frequent cause of denial. Insurers generally do not pay for the stockings themselves, though HSA funds can usually be used to buy them.
There are exceptions. Aetna waives the conservative trial for patients who have already undergone vein stripping or ablation and are experiencing recurrent varicosities in the same leg. Patients with active venous ulcers or significant hemorrhage can also be fast-tracked.
Which Procedures Insurance Covers
When the clinical criteria are met, most major insurers cover:
- Endovenous laser ablation (EVLT), which seals the vein with laser energy.
- Radiofrequency ablation (RFA), which uses radiofrequency energy for the same purpose.
- Vein stripping and ligation, the traditional surgical approach.
- Sclerotherapy, when used on veins 2.5 millimeters or larger (Aetna’s threshold) for medically necessary conditions rather than cosmetic spider veins. Most insurers cap coverage at about three sessions per leg within a 12-month period.
- Ambulatory phlebectomy, when the veins meet size thresholds and the underlying reflux is being treated.
VenaSeal, which uses a medical adhesive to close the vein, has moved into the covered column at most major insurers over the past year. UnitedHealthcare began covering it as medically necessary in July 2025, using the same criteria it applies to laser and radiofrequency ablation. Anthem, through its Carelon utilization management arm, expanded VenaSeal coverage effective January 2026. A coalition of eight medical societies, including the Society for Vascular Surgery and the American College of Cardiology, has cited five-year outcomes comparable to radiofrequency ablation. Aetna remains the holdout, classifying VenaSeal as experimental, investigational, or unproven as of its May 2025 policy review; the medical society coalition has called Aetna the “last outlier” among major insurers on this procedure.
Procedures that remain largely excluded include mechanochemical ablation (MOCA, marketed as ClariVein), which UnitedHealthcare, Aetna, and Cigna classify as experimental or unproven, and porcine bioprosthetic valve implants (VenoValve). Treatment of veins smaller than 2.5 to 3 millimeters is categorized as cosmetic.
How Coverage Varies by Plan Type
Medicare
Medicare covers varicose vein treatment under Local Coverage Determinations. The most current LCD, L34536, was revised in August 2025. It requires a failed three-month trial of conservative management, documented symptoms (pain impairing mobility, recurrent phlebitis, non-healing ulcers, bleeding, stasis dermatitis, or refractory edema), and appropriate imaging. Procedures on asymptomatic varicose veins or spider veins are denied as cosmetic. Under Part B, you pay 20% coinsurance after your deductible, which works out to roughly $362 for endovenous ablation at an ambulatory surgical center or $660 at a hospital outpatient department.
TRICARE
TRICARE covers treatment of saphenous venous reflux with symptomatic varicose veins when all clinical criteria are met: reflux of at least 500 milliseconds on duplex ultrasound, vein diameter of at least 3.5 millimeters, no deep vein thrombosis, and either hemorrhage, venous ulcer, or a failed three-month conservative trial. Covered procedures include endovenous radiofrequency ablation and endovenous laser ablation. Sclerotherapy for spider veins is explicitly not covered.
Medicaid
UnitedHealthcare’s Community Plan, which administers Medicaid managed care in many states, covers radiofrequency ablation, laser ablation, stripping, foam sclerotherapy, and VenaSeal when clinical criteria are met. The policy defers to state-specific guidelines in Idaho, Kansas, Kentucky, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Pennsylvania, and Tennessee, so coverage can vary meaningfully by state.
Employer-Sponsored Plans
Most employer-sponsored plans follow clinical criteria similar to the major insurers’ published policies. Large employers that self-insure under ERISA are exempt from state insurance mandates and have broad flexibility to design their own benefits. Self-funded plans often voluntarily include benefits comparable to fully insured plans, but there’s no guarantee. Check your plan documents, because the employer, not the carrier administering the claims, decides what’s covered.
ACA Marketplace Plans
Marketplace plans must cover ambulatory patient services as one of the ten essential health benefit categories, and outpatient varicose vein procedures fall under that umbrella. The specific services covered within the category vary by state and plan, and medical necessity still applies.
What You’ll Still Pay
Approval doesn’t mean zero cost. You remain responsible for your deductible, copays, and coinsurance. Deductibles on current plans range from $1,000 to $10,000. Office visit copays typically run $10 to $80. Coinsurance is commonly 10% to 20%, so a procedure with a $2,000 allowed amount leaves you owing $400 at 20%.
Where the procedure is performed matters as much as the procedure itself. Hospital-affiliated outpatient centers charge facility fees that can double or triple the total cost compared with an independent office or ambulatory surgical center. Medicare’s own data illustrates the gap: a stab phlebectomy costs about $95 in patient coinsurance at a surgical center versus $659 at a hospital outpatient department.
You can request a Good Faith Estimate from your provider before the procedure, and you have the right to dispute a final bill that exceeds the estimate by $400 or more.
If Your Claim Is Denied
Denials for varicose vein treatment are common and are often overturned on appeal. The usual reasons are insufficient reflux duration on ultrasound, vein diameter below the insurer’s threshold, gaps in the conservative treatment documentation, and coding errors.
Appeals typically run in two stages. First, your treating physician can request a peer-to-peer review, a phone call with a medical director at the insurer to present the clinical case. The doctor walks through your symptoms, reviews the ultrasound data, and argues for the medical benefit. Vein practices report a high success rate at this step.
If the internal appeal fails, federal law gives you the right to an external review by an independent third party, and at that stage the insurer no longer has the final say. Insurers must explain the reason for any denial and disclose how to appeal, and patients with urgent medical needs can request an expedited review.